Every Form 4 that Kiniksa Pharmaceuticals International, plc (KNSA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KNSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KNSA filings page.
Kiniksa Pharmaceuticals International, plc (KNSA) reported insider equity activity by its chief financial officer, Mark Ragosa, on September 1, 2026. He received a grant of 7,800 Restricted Share Units and a share option for 31,150 Class A Ordinary Shares at an exercise price of $79.28 per share, with long-term vesting schedules. On the same date, several earlier RSU grants vested and were converted into Class A Ordinary Shares, and 4,404 shares were delivered or withheld for payment of exercise price or tax liability. No Rule 10b5‑1 trading plan is reported.
Kiniksa Pharmaceuticals International, plc (KNSA) reported multiple equity compensation and related transactions for Chairman & CEO Sanj K. Patel on September 1, 2026. He received 30,050 Restricted Share Units and a share option for 120,150 Class A Ordinary Shares at $79.28 per share, both vesting over time. On the same date, previously granted RSUs covering 31,318 shares were exercised into Class A Ordinary Shares, which were acquired indirectly by The Patel Family Irrevocable Trust of 2025, and 15,144 shares were delivered or withheld at $79.28 per share to pay the exercise price or tax liability. Following these and prior transactions, indirect holdings include 109,795 shares in The Marina 2016 Irrevocable Trust and 51,794 shares in The Anglia 2013 Revocable Trust.
Kiniksa Pharmaceuticals International, plc (KNSA) reported that chairman and CEO Sanj K. Patel received equity awards on September 1, 2026. He was granted 30,050 Restricted Share Units, each representing one Class A Ordinary Share, and 120,150 share options with an exercise price of $79.28 per share expiring on August 31, 2036. On the same date, several previously granted Restricted Share Units vested and were converted into Class A Ordinary Shares held indirectly through The Patel Family Irrevocable Trust of 2025, with 15,144 shares delivered or withheld to cover the exercise price or tax liability at $79.28 per share. Indirect holdings also include 109,795 Class A Ordinary Shares held by The Marina 2016 Irrevocable Trust and 51,794 Class A Ordinary Shares held by The Anglia 2013 Revocable Trust. No Rule 10b5-1 trading plan is reported for these transactions.
Kiniksa Pharmaceuticals International, plc (KNSA) reported that its chief medical officer, John F. Paolini, received equity awards and had previously granted RSUs vest on September 1, 2026. He was granted 6,700 Restricted Share Units, each representing one Class A Ordinary Share, vesting in four annual installments starting September 1, 2026, and a share option for 26,750 Class A Ordinary Shares at an exercise price of $79.28 per share, expiring August 31, 2036, with vesting beginning September 1, 2026. On the same date, RSUs from earlier grants dated September 1, 2022, 2023, 2024, and 2025 vested, resulting in the exercise or conversion of 8,328 RSUs into Class A Ordinary Shares. Of the shares issued upon these vestings, 4,029 Class A Ordinary Shares were delivered or withheld at $79.28 per share for payment of exercise price or tax liability. No Rule 10b5-1 trading plan is reported for these transactions.
Kiniksa Pharmaceuticals International, plc (KNSA) reported that Chief Operating Officer Ross Moat received equity awards and exercised existing awards on September 1, 2026. He was granted 9,250 Restricted Share Units, plus a Share Option for 36,950 Class A Ordinary Shares at an exercise price of $79.28. Several prior RSU grants totaling 8,285 units were exercised into the same number of Class A Ordinary Shares, and 4,007 shares were delivered or withheld to pay the option exercise price or tax liability. The new RSUs and options generally vest over four years starting on September 1, 2026, with 25% vesting on the first anniversary and the remainder in subsequent installments. No Rule 10b5-1 trading plan is reported.
Kiniksa Pharmaceuticals International, plc (KNSA) disclosed that Chief Accounting Officer Michael R. Megna reported multiple equity transactions. On September 3, 2026, he sold 4,600 Class A Ordinary Shares at $80.30 per share under a Rule 10b5-1 trading plan executed on May 24, 2025. On September 1, 2026, he received a grant of 3,650 Restricted Share Units and a grant of 14,600 share options exercisable at $79.28 per share, plus several RSU conversions into Class A Ordinary Shares and a disposition of 5,531 shares at $79.28 for payment of exercise price or tax liability. He also voluntarily reported acquiring 279 shares at $33.50 on July 15, 2026 under the 2018 Employee Share Purchase Plan.
Kiniksa Pharmaceuticals International, plc (KNSA) director Barry D. Quart reported a bona fide gift of 2,600 Class A Ordinary Shares on 2026-08-19. The gift transferred shares at a reported price of $0.00 per share to a donor advised fund. Following this transaction, Quart directly holds 12,745 Class A Ordinary Shares.
Kiniksa Pharmaceuticals International, plc director Richard S. Levy received an award of 403 Restricted Share Units on August 1, 2026. Each RSU represents a contingent right to receive one Class A Ordinary Share and vested immediately upon grant. The RSUs were then exercised and converted into 403 Class A Ordinary Shares, bringing his direct holdings to 22,359 shares, with no share sales reported.
Cole G Bradley, a director of Kiniksa Pharmaceuticals International, plc, reported two share dispositions on 29 July 2026. He sold 3,673 Class A Ordinary Shares at $81.43 per share and made a bona fide gift of 4,500 shares to a donor advised fund. The Rule 10b5-1 trading plan box was not checked.
Kiniksa Pharmaceuticals International, plc reported that its chief strategy officer, Dhiraj H. Malkani, received several equity awards on July 1, 2026. These include performance share units, performance share options and restricted share units, each linked to Class A Ordinary Shares.
The grants comprise 1,307 and 1,245 Performance Share Units, 2,188 and 2,119 Performance Share Options with a $62.88 exercise price, 14,000 Restricted Share Units, and 82,600 Share Options also at $62.88 per share. The options expiring on June 30, 2036 generally vest over time or upon specific milestones.
Footnotes explain that RSUs vest in annual installments starting July 1, 2026, while Performance Share Units and Performance Share Options vest only if Kiniksa submits a biologics license application for KPL-387 for recurrent pericarditis and, for certain awards, if the FDA approves its commercial sale and marketing in the United States.
Kiniksa Pharmaceuticals International, plc director Barry D. Quart reported compensation-related equity activity. He exercised vested Restricted Share Units (RSUs) into 2,799 Class A Ordinary Shares, bringing his directly held Class A Ordinary Shares to 15,345.
Quart also received new equity awards on May 29, 2026. He was granted 2,026 RSUs, each representing one Class A Ordinary Share, which vest in full on the earlier of the first anniversary of the grant date or the company’s next annual shareholder meeting. In addition, he received options for 12,158 Class A Ordinary Shares at an exercise price of $48.38, vesting in twelve substantially equal monthly installments over roughly one year.
Kiniksa Pharmaceuticals International, plc director Kimberly J. Popovits reported routine equity compensation transactions. On May 29, 2026, she exercised 2,799 Restricted Share Units into an equal number of Class A Ordinary Shares, bringing her direct Class A Ordinary Share holdings to 15,345 shares after the transaction.
On the same date, she received new awards of 2,026 Restricted Share Units and a share option for 12,158 Class A Ordinary Shares at an exercise price of $48.38 per share. The option vests in twelve substantially equal monthly installments starting from the May 29, 2026 grant date, and the RSUs vest in full on the earlier of the first anniversary of the grant or the next annual shareholder meeting.
Kiniksa Pharmaceuticals International, plc reported that trusts associated with Chairman and CEO Sanj K. Patel adjusted their holdings of ordinary shares. The Anglia 2013 Revocable Trust converted 900,000 Class B Ordinary Shares into 900,000 Class A Ordinary Shares at a stated price of $0.00 per share, a non-cash derivative conversion rather than a market trade.
After this conversion, the Anglia 2013 Revocable Trust holds 951,794 Class A Ordinary Shares and 626,160 Class B Ordinary Shares. Separate family trusts report indirect holdings of 76,174 and 109,795 Class A Ordinary Shares. The filing reflects changes in share classes held through family trusts, not open-market buying or selling.
Kiniksa Pharmaceuticals International, plc director Tracey L. McCain reported routine equity compensation activity. McCain exercised 2,799 Restricted Share Units (RSUs) into 2,799 Class A Ordinary Shares, bringing direct holdings in the shares to 15,345. The filing also shows a new grant of 2,026 RSUs and a separate grant of share options for 12,158 Class A Ordinary Shares at an exercise price of $48.38 per share. The option vests in twelve substantially equal monthly installments following the May 29, 2026 grant date, while the new RSUs vest in full on the earlier of the first anniversary of the grant date or the next annual shareholder meeting.
Kiniksa Pharmaceuticals director Thomas Malley reported equity compensation transactions and updated holdings. On May 29, 2026, he exercised 2,799 Restricted Share Units, receiving the same number of Class A Ordinary Shares at a stated price of $0.00 per share.
On the same date, he received a new grant of 2,026 Restricted Share Units and a share option for 12,158 Class A Ordinary Shares with an exercise price of $48.38 per share. The option vests in twelve substantially equal monthly installments following the grant date, with the final installment vesting on the earlier of the first anniversary of the grant or the issuer’s next annual meeting of shareholders.
Following these transactions, Malley directly holds 15,345 Class A Ordinary Shares. An additional 71,967 Class A Ordinary Shares are held indirectly through Mossrock Capital, LLC, where he serves as president and may be deemed to beneficially own those shares.
Kiniksa Pharmaceuticals International, plc director Richard S. Levy reported routine equity compensation activity. He exercised 2,799 Restricted Share Units, receiving the same number of Class A Ordinary Shares, bringing his direct holdings in that class to 21,956 shares.
On the same date, he received new grants of 2,026 Restricted Share Units and a share option covering 12,158 Class A Ordinary Shares at an exercise price of $48.38 per share. Footnotes state the option vests in twelve substantially equal monthly installments over roughly one year, while the new RSUs vest in full on the earlier of the grant anniversary or the company’s next annual shareholder meeting.
Kiniksa Pharmaceuticals International, plc director Cole G. Bradley reported equity compensation transactions. Bradley exercised 2,799 Restricted Share Units that vested in a single installment into the same number of Class A Ordinary Shares, bringing his direct holdings to 15,345 shares. He also received 2,026 new Restricted Share Units that each represent one Class A Ordinary Share, vesting in full on the earlier of the grant anniversary or the next annual shareholder meeting. In addition, he was granted options on 12,158 Class A Ordinary Shares at an exercise price of $48.38 per share, vesting in twelve substantially equal monthly installments and expiring in 2036.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
Kiniksa Pharmaceuticals International, plc reported compensation-related equity grants to directors affiliated with Baker Bros. funds. On May 29, 2026, each of Felix J. Baker, Dr. Stephen R. Biggar and M. Cantey Boyd received 2,026 restricted share units (RSUs) and 12,158 non-qualified share options tied to Class A Ordinary Shares under the 2018 Incentive Award Plan. The RSUs vest on the earlier of May 29, 2027 or the next annual shareholder meeting, subject to continued board service, while the share options have a strike price of $48.38, vest in 12 monthly installments beginning June 29, 2026, and expire on May 28, 2036. The Form 4 attributes indirect pecuniary interests in these awards to 667, L.P. and Baker Brothers Life Sciences LP, with Baker Bros. Advisors LP holding voting and dispositive power, and Julian C. Baker and Felix J. Baker disclaiming beneficial ownership beyond their pecuniary interests.
Kiniksa Pharmaceuticals International, plc Chief Medical Officer John F. Paolini reported an exercise-and-sell transaction in Class A Ordinary Shares. On May 1, 2026, he exercised options to acquire 58,424 shares at $10.36 per share and then sold the same number of shares in two open-market transactions at weighted average prices of $53.52 and $54.04. The sales were executed through a broker under a pre-arranged Rule 10b5-1 trading plan. Following the exercise, 29,670 share options remained outstanding and are fully vested, with an expiration date in February 2028.
Kiniksa Pharmaceuticals International, plc Chairman and CEO Sanj K. Patel reported an exercise-and-sale transaction in Class A Ordinary Shares. He exercised share options to acquire 48,565 shares at $30.93 per share and then sold 48,565 shares in an open-market transaction at a weighted-average price of $54.02 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan dated October 31, 2025. Following these direct transactions, his directly held Class A Ordinary Shares were reduced to zero, while separate indirect holdings remain in several family trusts.
Kiniksa Pharmaceuticals International, plc director and CEO Sanj K. Patel reported a series of option exercises and related share sales in late April. He exercised options to acquire a total of 508,339 Class A Ordinary Shares at exercise prices of $10.36 and $30.93 per share, then sold the same number of shares in open-market transactions.
The reported sales occurred on April 28–30, 2026, at weighted average prices generally between $50.00 and about $54.23 per share, under a pre-arranged Rule 10b5-1 trading plan executed on October 31, 2025. After these transactions, filings show continued indirect ownership through family trusts, including 51,794, 109,795 and 76,174 Class A Ordinary Shares held by separate Patel family trusts, and remaining vested options for 48,565 shares at a $30.93 exercise price expiring in 2028.
Kiniksa Pharmaceuticals International, plc director Barry D. Quart executed an option exercise-and-sale transaction in Class A Ordinary Shares. He exercised options to acquire 13,099 shares at $14.33 per share and sold 13,099 shares at a weighted average price of $50.10 under a pre-arranged Rule 10b5-1 plan. The sale occurred in multiple broker-dealer trades between $50.00 and $50.725. After these transactions, he directly holds 12,546 shares and 13,237 remaining share options that are fully vested and exercisable, expiring on June 28, 2031.
Kiniksa Pharmaceuticals International, plc chief accounting officer Michael R. Megna reported an open-market sale of 6,625 Class A Ordinary Shares at $46.69 per share on April 9, 2026. After this transaction, he directly holds 27,418 shares. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance rather than timed discretionarily.
Kiniksa Pharmaceuticals International, plc chief operating officer Moat Ross reported an open-market sale of 1,703 Class A Ordinary Shares on April 9, 2026 at $46.69 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan entered on November 13, 2024, and Ross now directly holds 12,029 shares.
Kiniksa Pharmaceuticals International, plc chief strategy officer Eben Tessari exercised Restricted Share Units into common shares and had shares withheld for taxes. On April 7, 2026, 2,726 RSUs were converted into 2,726 Class A Ordinary Shares. Of these, 846 shares at $48.94 per share were withheld to satisfy tax obligations, leaving Tessari with 23,130 Class A Ordinary Shares held directly. Each RSU represents a right to receive one Class A Ordinary Share and the RSU grant vests in four equal annual installments starting on April 7, 2023, over a four-year period.
Kiniksa Pharmaceuticals International, plc chief financial officer Mark Ragosa exercised 2,694 Restricted Share Units into Class A Ordinary Shares on April 7, 2026. Each RSU converts into one share and is part of a grant that vests in four equal annual installments starting April 7, 2022.
To cover tax obligations from this vesting, 1,303 Class A Ordinary Shares were withheld at a price of $48.94 per share, rather than sold in the open market. After these compensation-related transactions, Ragosa directly holds 16,154 Class A Ordinary Shares.
Kiniksa Pharmaceuticals International, plc Chairman & CEO Sanj K. Patel reported multiple equity transactions in the company’s Class A Ordinary Shares. On April 6, 2026, he exercised options for 7,278 shares at $10.36 per share and sold 7,278 shares at a weighted average price of about $50.01 in an open-market transaction executed under a pre-arranged Rule 10b5-1 trading plan.
On April 7, 2026, 9,991 Restricted Share Units converted into the same number of Class A Ordinary Shares, credited to The Patel Family Irrevocable Trust of 2025. Of these, 4,831 shares were withheld at $48.94 per share to cover tax obligations, leaving 76,174 shares in that trust. Additional indirect holdings include 109,795 shares in The Marina 2016 Irrevocable Trust and 51,794 shares in The Anglia 2013 Revocable Trust.
Kiniksa Pharmaceuticals’ chief medical officer John F. Paolini exercised 2,497 Restricted Share Units into Class A Ordinary Shares on April 7, 2026. Of these shares, 1,208 were withheld at $48.94 per share to cover tax obligations, and he now directly holds 65,623 Class A Ordinary Shares. The RSUs come from a grant that vests over four years, with 25% vesting on each anniversary of the April 7, 2022 grant date.
Kiniksa Pharmaceuticals International, plc chief operating officer Ross Moat reported a series of equity transactions involving Class A Ordinary Shares. On April 7, 2026, he exercised 2,477 Restricted Share Units, receiving an equal number of Class A Ordinary Shares as the RSUs converted one-for-one.
On the same date, 774 shares were disposed of at $48.94 per share to cover tax obligations related to the equity award, a non-market tax-withholding transaction. On April 6, 2026, he completed an open‑market sale of 2,367 Class A Ordinary Shares at $48.58 per share under a pre‑arranged Rule 10b5‑1 trading plan. Following these transactions, he directly holds 12,029 Class A Ordinary Shares.
Kiniksa Pharmaceuticals International, plc chief accounting officer Michael R. Megna exercised restricted share units and had shares withheld for taxes. On this date, 3,932 Restricted Share Units converted into 3,932 Class A Ordinary Shares. Of these, 1,666 shares were disposed of to cover tax obligations at a price of $48.94 per share, a non-market tax-withholding transaction. After these compensation-related events, Megna directly held 34,043 Class A Ordinary Shares. The RSUs vest over four years, with 25% vesting on each yearly anniversary of the April 7, 2022 grant date.
Kiniksa Pharmaceuticals International, plc director Barry D. Quart exercised stock options and sold the resulting shares in a planned transaction. On April 6, 2026, he exercised options for 6,901 Class A Ordinary Shares at $14.33 per share, then sold the same 6,901 shares at a weighted average price around $50.00 under a pre-arranged Rule 10b5-1 trading plan. His direct ownership of Class A Ordinary Shares remained at 12,546 shares after the transactions, while his remaining option position decreased by the exercised amount.
Kiniksa Pharmaceuticals International, plc Chief Strategy Officer Eben Tessari reported several equity compensation transactions. On April 1, 2026, Tessari received a grant of 33,200 share options for Class A Ordinary Shares at an exercise price of $48.13 per share, expiring on March 31, 2036. The option vests 25% on April 1, 2027, then in 36 monthly installments.
On the same date, Tessari was granted 8,300 Restricted Share Units (RSUs) and 16,600 Performance Share Units (PSUs), each tied to Class A Ordinary Shares. The RSUs vest over four years, with 25% vesting on April 1, 2026 and annually thereafter. The PSUs convert into up to 200% of one share each, based on performance, no later than January 30, 2028.
Also on April 1, 2026, previously granted RSUs vested and were settled into 5,975 Class A Ordinary Shares. Of these, 1,756 shares were withheld at $48.13 per share to satisfy tax obligations, a non‑market disposition, leaving Tessari with 21,250 Class A Ordinary Shares held directly after the transactions. Earlier, on January 15, 2026, Tessari acquired 365 shares at $24.16 per share through the company’s 2018 Employee Share Purchase Plan, an acquisition exempt under Rule 16b‑3(e).
Kiniksa Pharmaceuticals International, plc reported that Chief Financial Officer Mark Ragosa received new equity awards and saw prior awards vest into shares. On April 1, 2026, he was granted 31,150 share options with an exercise price of $48.13 per share, vesting over four years, and expiring in 2036.
He also received 7,800 Restricted Share Units and 15,600 Performance Share Units, each tied to one Class A Ordinary Share, with PSUs payable based on performance and eligible to convert into up to 200% of one share by January 30, 2029. Existing RSUs vested into 5,187 Class A Ordinary Shares, of which 2,510 shares were withheld at $48.13 per share to cover tax obligations, leaving Ragosa holding 14,763 Class A Ordinary Shares directly.
Kiniksa Pharmaceuticals International, plc director and CEO Sanj K. Patel reported equity compensation grants and related share movements. On April 1, 2026, he received a grant of 120,150 share options with an exercise price of $48.13 per share, expiring on March 31, 2036, which vest over time starting April 1, 2026.
He was also granted 30,050 Restricted Share Units (RSUs) vesting over four years from April 1, 2026, and 60,100 Performance Share Units (PSUs), each representing a contingent right to receive Class A Ordinary Shares based on performance and vesting no later than January 30, 2029 at up to 200% of target.
In addition, previously granted RSUs totaling 21,327 units converted into the same number of Class A Ordinary Shares held indirectly through The Patel Family Irrevocable Trust of 2025. Of these, 10,313 shares were disposed of to satisfy tax obligations at $48.13 per share, leaving the trust with 71,014 shares. Separate trusts indirectly hold 109,795 and 51,794 Class A shares, reflecting substantial ongoing ownership.
Kiniksa Pharmaceuticals International, plc reported multiple equity awards and related exercises for its Chief Medical Officer, John F. Paolini, on April 1, 2026. He received a share option for 26,750 Class A Ordinary Shares at an exercise price of $48.13 per share, expiring on March 31, 2036, that vests over time starting April 1, 2026.
He was also granted 6,700 Restricted Share Units and 13,400 Performance Share Units, each linked to Class A Ordinary Shares and subject to four-year time-based or performance-based vesting, with PSUs eligible to convert into up to 200% of one share each by January 30, 2029. In addition, Paolini exercised previously granted RSUs for 5,831 Class A Ordinary Shares, with 2,821 shares withheld at $48.13 per share to cover tax obligations.
Following these transactions, Paolini directly holds 64,334 Class A Ordinary Shares, reflecting routine compensation-related equity activity rather than open-market buying or selling.
Kiniksa Pharmaceuticals International, plc chief operating officer Ross Moat reported multiple equity awards and related share activity. On April 1, 2026, he received a share option grant for 36,950 shares with an exercise price of $48.13 per share, expiring on March 31, 2036.
He was also granted 9,250 Restricted Share Units and 18,500 Performance Share Units, each tied to Class A Ordinary Shares and subject to multi‑year vesting and, for PSUs, performance criteria through January 30, 2029. On the same date, he exercised previously granted RSUs into 5,808 Class A Ordinary Shares, with 1,706 shares withheld at $48.13 per share to cover tax obligations.
Following these transactions, Moat held 14,396 Class A Ordinary Shares directly. Earlier, on January 15, 2026, he acquired 879 Class A Ordinary Shares at $24.16 per share under the company’s 2018 Employee Share Purchase Plan, an acquisition noted as exempt under Rule 16b‑3(e).
Kiniksa Pharmaceuticals International, plc chief accounting officer Michael R. Megna reported multiple equity compensation transactions. On April 1, 2026, he received a share option for 14,600 shares at an exercise price of $48.13, vesting over four years starting April 1, 2026.
He was also granted 3,650 Restricted Share Units and 7,300 Performance Share Units, each tied to Class A Ordinary Shares and subject to multi‑year time- and performance-based vesting. The filing shows RSU exercises converting into 7,564 Class A Ordinary Shares, with 3,205 shares withheld at $48.13 to cover tax obligations.
Following these transactions, Megna directly holds 31,777 Class A Ordinary Shares. Footnotes describe prior participation in the 2018 Employee Share Purchase Plan and detail vesting schedules for the options, RSUs, and PSUs, including potential PSU settlement by January 30, 2029 based on performance.
Kiniksa Pharmaceuticals International, plc Chief Financial Officer Mark Ragosa exercised stock options and sold shares in a planned transaction. On March 9, 2026, he exercised options covering 36,722 Class A Ordinary Shares at exercise prices between $17.76 and $26.74 per share. The same day, he sold 17,981 shares at $45.58 per share and 18,741 shares at $46.24 per share in open‑market transactions. These sales, totaling 36,722 shares, were carried out under a pre‑arranged Rule 10b5‑1 trading plan executed on August 14, 2025. Following the transactions, Ragosa directly owned 12,086 Class A Ordinary Shares.
Kiniksa Pharmaceuticals International, plc Chief Medical Officer John F. Paolini exercised options and sold shares of Class A Ordinary Shares. He exercised a fully vested option for 40,000 Share Options at an exercise price of $10.36 per share, acquiring 40,000 Class A Ordinary Shares on March 2, 2026. That same day, he sold a total of 40,000 Class A Ordinary Shares in open-market transactions at weighted average prices ranging from about $43.555 to $46.09, under a Rule 10b5-1 plan executed on November 18, 2025. After these transactions, he directly holds 61,324 Class A Ordinary Shares and 58,424 Share Options.
Kiniksa Pharmaceuticals International, plc director Quart Barry D reported option exercises and share sales in February 2026 under a pre‑arranged Rule 10b5‑1 trading plan executed on September 11, 2025.
On February 10 and February 12, Barry exercised share options at an exercise price of $15.47 per Class A ordinary share and immediately sold the resulting shares in open-market transactions at $45 per share. Across both dates, 2,800 Class A ordinary shares were sold while maintaining 12,546 Class A ordinary shares held directly after the reported transactions. The options involved were fully vested and exercisable.
Kiniksa Pharmaceuticals International, plc chief financial officer Mark Ragosa reported option exercises and share sales in the company’s Class A ordinary shares. On February 9, 2026, he exercised options for 8,374 shares at $12.97 and 2,471 shares at $16.90, converting them into the same number of shares.
On the same date, he sold 9,114 shares at a weighted average price of $42.85 and 8,731 shares at a weighted average price of $43.72 through a broker-dealer in multiple trades. These transactions were effected under a Rule 10b5-1 trading plan executed on August 14, 2025. After these trades, he directly held 12,086 Class A ordinary shares.
Kiniksa Pharmaceuticals International, plc director Quart Barry D reported option exercises and share sales in early February 2026 under a pre-arranged trading plan. On February 2, 3, and 4, he exercised fully vested share options at an exercise price of $15.47 per Class A Ordinary Share and sold the resulting shares in open-market transactions at weighted average prices of $45.00, $45.27, and $45.02, respectively.
The transactions were effected pursuant to a Rule 10b5-1 plan executed on September 11, 2025. After these trades, he directly beneficially owned 12,546 Class A Ordinary Shares and 2,800 share options that are fully vested and exercisable.
Kiniksa Pharmaceuticals International, plc director Richard S. Levy reported equity compensation activity involving restricted share units and ordinary shares. On February 1, 2026, he received a grant of 683 Restricted Share Units, each representing the right to receive one Class A Ordinary Share.
The RSUs vested immediately upon grant on February 1, 2026 and had no expiration date. On the same date, 683 RSUs were settled, resulting in the acquisition of 683 Class A Ordinary Shares at a price of $0. Following these transactions, Levy directly owned 19,157 Class A Ordinary Shares.
Kiniksa Pharmaceuticals International, plc reported that its Chief Financial Officer, Mark Ragosa, sold 12,000 Class A ordinary shares on January 8, 2026. The sale was coded as an open-market disposition and was carried out at a weighted average price of $41.89 per share, through multiple trades within a disclosed price range. The transaction was completed under a pre-arranged Rule 10b5-1 trading plan that the reporting person executed on August 14, 2025, indicating the sale followed a preset schedule rather than ad hoc market timing. Following this transaction, the CFO directly beneficially owns 19,086 Class A ordinary shares of the company.
Kiniksa Pharmaceuticals International, plc director reports option exercise and share sale. On 12/15/2025, the reporting person exercised a share option for 20,129 Class A ordinary shares at an exercise price of $10.36 per share and acquired these shares. On the same date, they sold 20,129 Class A ordinary shares in broker-dealer trades at a weighted average price of $41.51 per share, with individual trade prices ranging from $41.19 to $41.78. After these transactions, the director beneficially owned 12,546 Class A ordinary shares directly, and held 0 derivative securities following the full exercise of the option, which was fully vested and exercisable. The transactions were made under a Rule 10b5-1 trading plan executed on September 11, 2025.
Kiniksa Pharmaceuticals International, plc reported an insider transaction by its Chief Operating Officer on 12/15/2025. The COO exercised an employee share option to acquire 6,000 Class A Ordinary Shares at an exercise price of $8.83 per share, then sold 12,048 Class A Ordinary Shares at a weighted average price of $41.56 per share through multiple trades.
After these transactions, the reporting person beneficially owned 16,666 Class A Ordinary Shares, held directly. The filing states that the trades were made under a pre-established Rule 10b5-1 trading plan executed on April 29, 2024, and notes that the option involved in this transaction was fully vested and exercisable.
Kiniksa Pharmaceuticals International, plc (KNSA) reported an insider equity transaction by its Chief Operating Officer on Form 4. On 11/17/2025, the COO exercised a share option for 6,500 Class A ordinary shares at an exercise price of $8.83 per share, then sold shares the same day in two broker-executed transactions under a pre-arranged Rule 10b5-1 trading plan dated April 29, 2024.
The sales included 645 shares at a weighted average price of $40.08 and 11,825 shares at a weighted average price of $41.30, both executed in multiple trades within stated price ranges. After these transactions, the COO directly beneficially owned 22,714 Class A ordinary shares and held 6,000 share options that are fully vested and exercisable.
Kiniksa Pharmaceuticals (KNSA): The Chairman & CEO reported bona fide gifts (Code G) of Class A ordinary shares. On 11/12/2025, 111,794 shares were gifted; on 11/13/2025, 60,000 shares were gifted. These entries were at a stated price of $0 per share.
After the transactions, reported holdings were 0 shares direct, and indirect balances included 51,794 shares held by The Anglia 2013 Revocable Trust, 60,000 shares held by The Patel Family Irrevocable Trust of 2025, and 109,795 shares held by The Marina 2016 Irrevocable Trust.
Kiniksa Pharmaceuticals (KNSA) disclosed a Form 4 showing its Chief Medical Officer executed pre‑planned transactions on 10/31/2025 under a Rule 10b5‑1 plan. The officer exercised options for 36,542 Class A ordinary shares at $3.80 and 46,000 shares at $8.83, then sold 82,542 shares at a weighted average price of $37.14 (trade range: $36.80–$37.675). Following these transactions, the filing reports 61,324 shares beneficially owned directly. The options exercised were fully vested and exercisable.
Kiniksa Pharmaceuticals (KNSA) reported an insider transaction by its Chief Financial Officer. On 10/28/2025, the CFO exercised 100 share options at $30.93 and sold 100 Class A Ordinary Shares at $41.00, executed under a Rule 10b5-1 plan dated September 3, 2024. Following these trades, the officer directly owned 31,086 shares and held 19,900 options with an expiration of 09/19/2028. The option was fully vested and exercisable.